Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019
Real-World Impact of Early Treatment With Intravitreal Dexamethasone Implant in DME in US Clinical Practice: Outcomes From the Vestrum Database
Roger A. Goldberg, MD, MBA
On Demand Cases, Courses, and Papers
2021
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022

Category: Diabetic Retinopathy

See more